Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2019	Jun. 30, 2018	[1]
Current assets:
Cash and cash equivalents	$ 93.2	$ 110.9
Marketable investment securities	43.7	69.7
Prepaid expenses	16.6	9.4
Inventory	31.4	34.3
Trade accounts receivable	133.9	99.5
Prepaid taxes	25.1
Other receivables	4.7	3.8
Total current assets	348.6	327.6
Property, plant and equipment, net	57.3	43.2
Long-term marketable investment securities	54.9	30.7
Intangibles, net	684.7	455.2
Goodwill	417.2	318.6
Total assets	1,562.7	1,175.3
Current liabilities:
Accounts payable	33.3	26.0
Accrued liabilities	78.9	68.3
Short-term contingent consideration	3.4	5.3
Deferred revenue	2.2	2.6
Total current liabilities	117.8	102.2
Unrecognized tax benefits	21.7	24.9
Other long-term liabilities	7.8	6.3
Contingent consideration	10.4	9.2
Long-term debt	233.5	9.3
Long-term deferred taxes	82.6	57.3
Total liabilities	473.8	209.2
Commitments and contingencies
Stockholders’ equity:
Common stock, 73.5 and 70.6 shares outstanding at June 30, 2019 and 2018 respectively	0.7	0.7
Additional paid-in capital	1,068.0	915.4
Accumulated other comprehensive loss	(5.4)	(4.1)
Retained earnings	25.6	54.1
Total Myriad Genetics, Inc. stockholders' equity	1,088.9	966.1
Total stockholders' equity	1,088.9	966.1
Total liabilities and stockholders’ equity	$ 1,562.7	$ 1,175.3

[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements of this report for additional information.